Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMED: Effects of Infusion Timing on Treatment Response in Solid Tumors
NCT07630168Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Aug 2026
- Primary completion
- Jan 2033
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (4 cohorts), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Progression-Free Survival at 2 years and Major Pathologic Response at 3 months. Started Aug 2026; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07630168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630168.